Transforming drug discovery through network biology
We operate at the intersection between computational power and biological insight.
We have developed a proprietary network-driven computational platform to uncover new ways to fight disease and accelerate the discovery of novel and better treatments for patients.
Our technologies can be applied to any area of biology and are rapidly able to produce actionable outcomes.
I am responsible for overseeing internal and external pre-clinical drug discovery programs through the utilisation of a network-driven approach to identify protein:protein interactions critical for disease modification and resolution. This is coupled with the identification and assessment of molecules capable of targeting and disrupting/enhancing those interactions. I am an in vitro pharmacologist with over 18 years’ experience in the pharmaceuticals industry where I led and managed the delivery of pre-clinical drug discovery projects across multiple Neuroscience therapeutic areas. I gained my degree and PhD at the University of Bath and am a Member of the Royal Society of Biology. In my spare time I am a full time dad, part-time dog walker, and occasional runner/swimmer/cyclist.
I have been instrumental in defining and developing the conceptual framework on which the network-driven drug discovery approach pioneered at e-therapeutics is based.
I moved from academia into biotech 13 years ago and have worked in both drug delivery and drug discovery. I am a clinician scientist with over 30 years’ experience in cell biology research and clinical medicine in a variety of roles including MRC Fellow, UCL Laboratory for Molecular Cell Biology, Visiting Fellow, The Jackson Laboratory USA, Lecturer & Medical Advisor UCL Institute of Ophthalmology, Hon Senior Lecturer UCL School of Pharmacy as well as senior clinical management positions. I gained a BSc (Biology & Computing), and a PhD in neuroscience from the University of London followed by postdoctoral work in Cambridge and medical studies at Oxford leading to the BM BCh in clinical medicine.
I have extensive experience in the biotechnology sector and financial markets. Recent roles include CEO of Silence Therapeutics plc from 2012-2018 as well as a founder shareholder of Evolution Group, a U.K. based Investment Bank, from 2001-2008. I am an experienced investor in small companies and has held numerous declarable stakes in listed and private biotechnology and technology companies.
I am a UK Chartered Patent Attorney and European Patent Attorney, with many years of intellectual property experience in the pharmaceutical and biotech industries. I have previously worked as in-house Patent Counsel for a range of pharmaceutical companies, such as Merck and Co., Glaxo Wellcome, PLIVA and more recently as Head of IP at Silence Therapeutics plc. I have also held senior patent attorney roles in several leading international law firms, and I have successfully represented many international pharmaceutical companies in high profile and pivotal patent cases before the European Patent Office. In recent years, I have developed a wealth of knowledge of the siRNA patent landscape and how to strategically operate in this IP space.
I am a software engineer with 15 years' experience building and maintaining large-scale information platforms, mainly in the healthcare space. Originally trained as a geneticist, I have always been driven by using technology to improve civilisation. At e-therapeutics I help to ensure our drug discovery platform and engineering team provides for all of our current needs, as well as being scalable for the future. Outside of work I'm a keen science fiction fan, love travel, history, and exploring the nearby Yorkshire Dales.
As Digital Operations Analyst my role primarily involves working with the Digital Operations team to assist with the implementation, management and procedure creation for new digital systems, alongside working on IT infrastructure. I have a background in Engineering, focusing on the delivery of technology solutions for new and existing customers. My spare time is mostly taken up by reading, music (both listening and producing) and gaming alone and with friends.
As a Scientific Programmer my role is to attend to the development and maintenance requirements of the platform.
I joined the company after completing a PhD in self-organising multi-agent architectures for smart-grid cyber-security from Newcastle University, a MSc in Advanced Software Engineering from Durham university and a BSc in Computer Forensics from Northumbria university.
My spare time is mostly filled with local theatre, both directing and acting.
As part of the informatics team, my role involves building new and proprietary tools to enhance capabilities of our in silico platform; but also extracting information from multi-scale genome datasets, with a strong emphasis in providing actionable insights for experimental validation.
I am computational biologist with a background in genetics (PhD in Genetics) and over 15 years' experience in academia and the biotech industry. I am specialised in the analysis of multi-scale genome datasets, statistics and computational modelling with a particular focus on the dynamics of biological systems.
I like to set up personal (non-scientific) projects which could take months or years. For example, the last couple of years I trained and run my first marathons. But I guess some of my recurring hobbies revolve around mountains and readings.
My role involves the application of the e-therapeutics platform technology to internal and partnered drug discovery projects. I oversee the progress of projects with our CRO partners and biopharma collaborators. By background I am a biochemist/cell biologist and have spent my career within the biopharma industry in both line and project management roles. I have been part of research teams in big/mid-size pharma companies, as well as smaller biotechs, and have worked with NCE and antibody discovery projects. Although I have probably spent most time in oncology, I have also worked in inflammation, anti-infectives and fibrosis. Outside of work my interests lie with my family, my dog and my garden, although my wife would say that the dog always comes first.
I have a keen interest in cutting-edge high throughput technologies whose niche is pipeline development, however I find great satisfaction in developing computational tools that lighten user workloads. Driven by new challenges, I am always eager to learn in whichever scientific direction I am pulled. My past-time therapy is bookbinding and collecting illustrated children’s fairy-tales. Over the weekends I can probably be found out-and-about on a country walk with my two children admiring the scenery be it: woods, estuary or seaside; or up in a Robin admiring the beautiful British tapestry below.
I am the Executive Assistant/Office Manager. I have over 30 years' experience working for both large and small Pharmaceutical and Biotech companies such as Baxter Healthcare, Genzyme, InterMune and Circassia Group Plc. In my spare time my husband and I enjoy watching our grown-up children, Megan and Jack play semi-pro Football, which takes us all over the country. I also enjoy cooking and spending time with family and friends.
I am a molecular cell biologist with over 20 years of target validation and drug discovery experience in biotech and biopharma. I have led projects and teams working on small molecule and antibody therapeutics within the oncology, metabolic and immunology disease areas. I gained a BSc in Biochemistry at the University of Manchester and a PhD in Molecular Oncology at the Paterson Institute for Cancer Research. Outside of work I enjoy spending time with my family, listening to progressive metal, playing guitar and cycling.
I am a Principal Computational Biologist at e-therapeutics. I develop systems biology and network approaches to understand the underlying biology of drugs and diseases. I apply network-based computational methods to multiple drug discovery projects.
I have done my PhD in Computational Biology at Imperial College London, UK and a post-doc in the University of Cambridge, UK. My research was focused on the study of disease mechanisms in polygenic diseases, in particular in cancer. I was trained in biochemistry, biostatistics, systems biology and computational biology, and have authored several peer-reviewed scientific articles and book chapters.
Outside work, I like to spend most of my time with my family and friends. I also enjoy going to the gym and practice Cross-Fit, playing tennis and going to the cinema.
I am a cell biologist with over 20 years experience in early drug discovery, I have performed and managed target and lead identification studies using small molecules, natural product extracts, antibodies and RNAi in both large pharma and biotech companies. Prior to joining e-therapeutics I had worked for 8 years in academia, where I was leading efforts in applying big data biology (combining genomic, transcriptomic, proteomic and phenotypic assays) and machine learning in order to identify signaling networks driving complex disease (cancer, multiple sclerosis and motor neuron disease). I will be applying similar, network-driven approaches, at e-therapeutics to advance the discovery pipeline.
I am responsible for conceptualizing, defining, and implementing the network-driven approach to drug discovery pioneered at e-therapeutics.
I have over 30 years-experience in applying computational approaches to the study of complex biological problems. My PhD (Newcastle, UK) and Post-doctoral (The Neurosciences Institute at The Scripps Research Institute, US) studies were in computational neuroscience focused on how networks of the brain give rise to perception and function. After leaving academia, I moved into applied bioinformatics and software engineering at a number of biotech companies in the San Francisco Bay Area. My role at e-therapeutics merges my academic and industry experience, designing and developing the informatics to drive our network-biology based approach to drug discovery.
Outside of work I am a keen, if not particularly skilful, mountain biker.
I am a computational biologist who is passionate about delivering high quality data and informative analyses to colleagues. My projects at e-therapeutics include the development as well as deployment of existing and bespoke computational approaches for multi-omics analyses and systems biology modelling (network reconstruction/inference and analysis).
I enjoy intrepid travels and discovering new cultures whenever possible. Otherwise, I spend most of my spare time exploring new recipes to share with friends and family, and afterwards convincing them to play one of my many board games for hours.
I am responsible for the oversight of the financial reporting, capital structure and risk management frameworks of e-therapeutics. My career history is weighted towards capital markets and corporate strategy with a history of public CFO, IPO and pharma/biotech experience. I received my BSc in Pharmacology from University College Dublin, MPhil and PhD degrees from the University of Cambridge and MSc (Finance) from London Business School.
I oversee our business and corporate development efforts, including securing and managing partnerships as well as maximising the value of our platform and the growth of the business. I work closely with the rest of the team to drive the execution of the corporate strategy.
My background is in advanced therapeutics and I have previously held senior BD and strategy positions at fast-paced organisations like Gyroscope Therapeutics and Silence Therapeutics. I received my PhD from Imperial College London, MRes in Biomedicine from UCL and BSc(Hons) in Biotechnology from UAB.
I love travelling, cooking and -the best part- eating. I also enjoy yoga and fitness and wish there were more hours in the day so I could learn to play a musical instrument!
I am an experienced disease biologist with 20 years' experience across biotech and academic sectors. At e-therapeutics, I lead projects in the cardiometabolic space and am programme manager for our recently launched GalNAc-siRNA platform. I previously led teams and projects at Imperial College London and at Duke-NUS Medical School Singapore where I was a Research Fellow. Most recently, at OxStem, I was Associate Director of Research, leading the heart failure programme and providing scientific guidance across a diverse portfolio. I keep fit by running and kickboxing though much prefer eating cheese or going to the pub (lockdown allowing). I am also an avid watcher of horror and science fiction films and occasionally play piano.
In my role at e-therapeutics, I utilize our platform to build and analyse biological network models of disease, and devise experiments for phenotypic screening of small molecule compounds. I have worked in a number of therapeutic areas, including neurodegenerative diseases and inflammation. I have a PhD in Pharmacology, and an MSc in Applied Bioinformatics. Following postdoctoral positions at The National Institutes of Health in the USA and at the RVC, University of London, I have spent the last 14 years working in the biotech sector, mainly in drug discovery. Outside of work, I have combined my love of sport and travel by becoming one of a small number of runners worldwide who have earned the Six Star Finisher medal for completing the six World Marathon Majors. My dream is to one day complete races on all seven continents! I am also a Leicester City FC season ticket holder, something which may have once been considered a curse rather than a pleasure, until recent miraculous exploits.
I work closely with the Chief Financial Officer on all internal and external financial reporting. I am an ACCA qualified accountant with 5 years’ experience in practice and over 5 years’ experience in the logistics and biotech industries. I like to be outdoors as much as possible, either gardening, walking, or trying out new sports. If my hobbies take me indoors, I like to cook and relax with friends and family.
I graduated from Newcastle University with a first (hons) in computing science in 2005. I took a job at, what is now, e-Therapeutics as a programmer shortly after completing my degree. I’m am currently a Senior Scientific Programmer and my main responsibilities are centred around platform development.
I am a software and systems architect with extensive experience in scientific workflows. Originally trained as a physicist, I spent many years at CERN, providing computing support for some of the experiments there. A few years ago I moved into computing for the life sciences, supporting research teams who need to make efficient use of HPC or cloud-based computing. I particularly enjoy being close to the science, where I can maximise my contribution and continue to learn. At e-therapeutics I am responsible for data and systems engineering, making our pipelines robust, reliable and scalable. When not at my computer I like walking in the countryside and wildlife-friendly gardening (i.e. not too tidy). My main hobby, since my childhood, is growing cacti.
Trevor was appointed to the Board in October 2015 as a Non-Executive Director and appointed Independent Non-Executive Chairman in March 2021. Trevor has over 40 years’ distinguished experience in the pharmaceutical and biotechnology industry as well as in academia. He is currently a NonExecutive Director of the life sciences investment company Arix Bioscience plc. He is also Visiting Professor at King’s College, London and holds honorary degrees and Gold Medals from seven universities. Previously, Trevor held significant roles in industry including Director of Allergan Inc. from 2005 to 2015 and R&D Director of The Wellcome Foundation from 1987 to 1994, where he was responsible for the development of AZT, Zovirax, Lamictal, Malarone and other medicines. Trevor has also held a number of advisory and regulatory roles including Director General of the Association of the British Pharmaceutical Industry (“ABPI”), Board member of the European Federation of Pharmaceutical Industry Associations (“EFPIA”) and the International Federation of Pharmaceutical Manufacturers Associations (“IFPMA”), a member of the UK Government regulatory agency, The Medicines Commission, a member of the UK Government Pharmaceutical Industry Ministerial Strategy Working Group on Pharmaceuticals, an adviser to the Cabinet Office on the Human Genome Project, a member of the Prime Minister’s Task Force on the Competitiveness of the Pharmaceutical Industry (“PICTF”) and Chair of the Government Advisory Group on Genetics Research.
Ali was appointed to the Board as Executive Chairman in February 2020, appointed Chief Executive Officer in October 2020 retaining his position as Chairman and subsequently splitting these roles in March 2021 and continues as Chief Executive Officer. Ali has extensive experience in the biotechnology sector and financial markets. Recent roles include Chief Executive Officer of Silence Therapeutics plc, from 2012 to 2018, as well as a founder shareholder of Evolution Group, a U.K. based Investment Bank, from 2001 to 2008. Ali is an experienced investor in small companies and has held numerous declarable stakes in listed and private biotechnology and technology companies.
Michael was appointed to the Board as a Non-Executive Director in February 2020. Michael is currently Chief Executive Officer of Sarossa plc. In addition, he is Chairman of Adams plc and Hardy plc and he is also a Non-Executive Director of Blake Holdings Limited and ORA Limited. Michael has been a Director of a number of other AIM quoted companies during the last ten years, including DeepMatter Group plc, Tissue Regenix Group plc, Nanoco Group plc and Ceres Power Holdings plc. Michael has a degree in Economics from Leeds University and is a member of the Institute of Chartered Accountants in England and Wales. His early career included working as an accountant and manager with PriceWaterhouse for 7 years in London and Abu Dhabi.
Our Scientific Advisory Board
Dr. Paul Burke is Principal of Burke Bioventures LLC, a Cambridge, Massachusetts-based biotechnology consultancy focused on translating research breakthroughs—particularly those based on nanotechnology, targeting, and RNA—into products. He provides strategic advice and scientific direction for biotechnology, pharmaceutical, and drug delivery companies and interim R&D management of venture-backed start-ups. Dr. Burke was formerly the founding head of Pfizer’s global Center of Excellence for targeted drug delivery and imaging, and Chief Technology Officer of the Oligonucleotide Therapeutics Unit. Previously he was Executive Director, RNA Therapeutics at Merck & Co. where he led delivery R&D, charged with developing enabling technologies for maximizing value from the company’s $1.1B acquisition of Sirna Therapeutics. The effort encompassed five discovery and preclinical departments and multiple external partnerships. Dr. Burke joined Merck following a decade-long tenure at Amgen, where he held positions of increasing responsibility including his most recent as Executive Director, Pharmaceutics. He received his B.S. in Chemistry with Distinction and Departmental Honors from Harvey Mudd College and his Ph.D. in Biological Chemistry from MIT. He is an Affiliate Professor of Bioengineering at the University of Washington and, for the winter 2017 term, was the Distinguished Visiting Professor at City of Hope’s Beckman Research Institute. Credit: Susan Wilson Photography (Photo)
John Mattick is Professor of RNA Biology at UNSW Sydney, and one of the world’s foremost experts in the field. He was previously the Chief Executive of Genomics England, Executive Director of the Garvan Institute of Medical Research in Sydney, Director of the Institute for Molecular Biology at the University of Queensland, and Director of the Australian Genome Research Facility. He has published over 300 scientific articles, which have been cited over 70,000 times. His work has received editorial coverage in Nature, Science, Scientific American and The New York Times, among others. His awards include the International Union of Biochemistry and Molecular Biology Medal, the Australian Government Centenary Medal, the University of Texas MD Anderson Cancer Center Bertner Award for Distinguished Contributions to Cancer Research, and the Human Genome Organisation Chen Medal for Distinguished Achievement in Human Genetics and Genomic Research.
Dr Harte is a pharmaceutical veteran and serial entrepreneur with more than 30 years in both research and executive positions. He currently serves as the Chief Translational Officer at the Case Western Reserve University School of Medicine advising and translating preclinical programs into patients. Previously, Bill had executive roles at Amgen, Bristol Myers Squibb, Visum Therapeutics and E3X therapeutics. Dr Harte’s broad experience spans computational chemistry, structural biology and modelling, medicinal chemistry, product development and portfolio prioritisation as well as CEO experience. Bill has also done extensive work with top-tier VC firms.